Iryna Yaryhina: Moving Beyond Episomal Fixes Toward Genomic Durability for Hemophilia
Iryna Yaryhina, Research Engineer at Pharmaceutical company «Zdorovye», shared on LinkedIn about a recent article by Nishal Kumarasamy et al, published in :
”Gene Editing for Hemophilia: Moving Beyond Episomal Fixes Toward Genomic Durability
Most approved gene therapies for hemophilia rely on AAV-mediated gene addition.
This approach works, but it remains limited by episomal expression, immune responses, and declining durability, especially for FVIII.
In a recent Frontiers in Bioengineering and Biotechnology review, ‘Exploring gene editing as a potential therapeutic strategy for hemophilia,’ the authors provide a systematic overview of how genome editing aims to address these fundamental constraints.
Instead of adding a functional gene copy, gene editing directly modifies the genome.
The goal is mutation correction, stable integration, or rebalancing of coagulation pathways.
Key highlights:
- A comparative analysis of ZFNs, TALENs, and CRISPR/Cas9, with clear discussion of efficiency, specificity, and translational readiness.
- Multiple editing strategies, including HDR and NHEJ, safe-harbour integration (albumin, AAVS1, H11), and direct correction of F8 and F9.
- The rise of base editing and prime editing for precise, double-strand-break–free correction of point mutations.
- AAV–LNP hybrid delivery approaches and CRISPR-based rebalancing strategies targeting anticoagulant pathways such as antithrombin.
- Early in vivo CRISPR clinical trials for hemophilia B, signalling a shift toward potentially permanent genomic correction.
Why this matters:
Hemophilia exposes a core limitation of classical gene therapy.
Expression without genomic integration rarely translates into long-term durability.
Genome editing reframes treatment as cell-heritable correction, while introducing new engineering constraints related to delivery, immune compatibility, and long-term safety.
Importantly, this review does not oversell the technology.
It maps the real biological and translational bottlenecks that will determine whether gene editing becomes clinically transformative or remains largely preclinical.”
Title: Exploring gene editing as a potential therapeutic strategy for hemophilia
Authors: Nishal Kumarasamy, Balaji Balakrishnan
Read the Full Article on Frontiers
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 11:36Ifeanyichukwu Ifechidere: From Running Tests to Trusting Interpretation in Coagulation
-
Apr 12, 2026, 11:30Zack Rosanova: What Happens to Your Brain Without Sleep
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine